Phase III trial of azacitidine and gilteritinib in FLT3 mutant AML

Azacitidine, venetoclax & gilteritinib in older/unfit patients with FLT3-mutated AMLПодробнее

Azacitidine, venetoclax & gilteritinib in older/unfit patients with FLT3-mutated AML

Update on Phase I/II study of azacitidine, venetoclax and gilteritinib in patients with FLT3+ AMLПодробнее

Update on Phase I/II study of azacitidine, venetoclax and gilteritinib in patients with FLT3+ AML

Triplet combination of azacitidine, venetoclax & gilteritinib for patients with FLT3-mutated AMLПодробнее

Triplet combination of azacitidine, venetoclax & gilteritinib for patients with FLT3-mutated AML

Updates from the Phase III LACEWING trialПодробнее

Updates from the Phase III LACEWING trial

Azacitidine, venetoclax and gilteritinib in previously untreated and R/R FLT3-mutated AMLПодробнее

Azacitidine, venetoclax and gilteritinib in previously untreated and R/R FLT3-mutated AML

AML data at ASH 2021 and implications on clinical practiceПодробнее

AML data at ASH 2021 and implications on clinical practice

FLT3-mutated AML data at ASH 2021Подробнее

FLT3-mutated AML data at ASH 2021

Популярное